Last reviewed · How we verify

BD MDI 40 µg — Competitive Intelligence Brief

BD MDI 40 µg (BD MDI 40 µg) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid inhaler. Area: Respiratory.

phase 2 Corticosteroid inhaler Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

BD MDI 40 µg (BD MDI 40 µg) — Pearl Therapeutics, Inc.. BD MDI 40 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BD MDI 40 µg TARGET BD MDI 40 µg Pearl Therapeutics, Inc. phase 2 Corticosteroid inhaler

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid inhaler class)

  1. Pearl Therapeutics, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BD MDI 40 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/bd-mdi-40-g. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: